Co-Diagnostics, Inc. to Participate at the Nasdaq Live from MarketSite Broadcast at Silicon Slopes 2025
MWN-AI** Summary
Co-Diagnostics, Inc. (Nasdaq-CM: CODX), a Utah-based molecular diagnostics company, is set to feature in the Nasdaq Live from MarketSite broadcast at the Silicon Slopes Summit 2025 on January 14, 2025. The event will showcase innovative leaders in the diagnostics industry, with Co-Dx CEO Dwight Egan likely to discuss the company's upcoming Co-Dx PCR platform and its array of diagnostic tests addressing infectious diseases, including COVID-19, tuberculosis, and HPV, as well as a multiplex panel for upper respiratory illnesses.
The Co-Dx™ Logix Smart® ABC test, which currently detects all known strains of H5N1, is being marketed as a Research Use Only (RUO) assay in the U.S. and as an in vitro diagnostic (IVD) in regions where CE markings are accepted. Additionally, the company has completed important design and analytical work for an H5N1-specific test that can either operate independently or integrate with existing tests. Co-Diagnostics has also found that its Mpox (2-Gene) RUO test remains effective against circulating strains, with plans for a more advanced 3-gene test.
As the U.S. faces a post-holiday COVID-19 surge, the company emphasizes its commitment to being prepared for potential health crises arising from infectious diseases. The broadcast will be accessible on Nasdaq’s Live from MarketSite webpage and through the company’s social media channels.
Co-Diagnostics employs advanced technologies to develop tests designed to detect and analyze nucleic acid molecules (DNA or RNA) and is focused on both infectious disease diagnostics and other genetic marker applications. The company’s forward-looking statements reflect ongoing regulatory reviews and the evolving landscape of public health threats.
MWN-AI** Analysis
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) is positioned for significant visibility and engagement during its upcoming participation in the Nasdaq Live from MarketSite broadcast at the Silicon Slopes Summit 2025 on January 14, 2025. This platform presents an opportunity for Co-Dx to highlight its innovative PCR technologies, especially its new diagnostic tests addressing persistent threats such as COVID-19 and emerging infectious diseases.
As the landscape of health crises evolves, Co-Diagnostics is focusing on diverse applications of its proprietary technology in molecular diagnostics. The Company has made substantial strides with its Co-Dx Logix Smart® ABC test for detecting multiple viral strains, including H5N1 and mpox, positioning itself advantageously as demand for robust diagnostic solutions continues to grow.
The anticipated announcement regarding the Co-Dx PCR platform and its capabilities to potentially mitigate future health threats can attract investor interest. Furthermore, the market’s ongoing surveillance for reliable healthcare solutions amid a backdrop of potential future pandemics adds to Co-Dx’s appeal. Investors should monitor the FDA approvals pending for the Co-Dx PCR Pro instrument and the COVID-19 Test, as they are critical milestones influencing the Company's revenue potential.
From a market perspective, CODX shares may present a compelling opportunity due to their valued innovations against a backdrop of continual health risks which often translate to increased healthcare expenditure. However, it is essential for investors to remain cautious; the Company faces inherent risks associated with regulatory approvals and market competition.
In summary, participation in the Nasdaq broadcast could catalyze CO-DX's visibility and growth narrative in the diagnostics sector. Investors are encouraged to analyze both the opportunities and risks presented by Co-Diagnostics as it showcases its transformative potential in public health solutions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
SALT LAKE CITY , Jan. 7, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be participating in Nasdaq's Live from MarketSite broadcast at the Silicon Slopes Summit 2025 on January 14, 2025 .
Live from MarketSite is Nasdaq's flagship broadcast opportunity, showcasing innovative leaders and disruptive companies in their fields. The interview with Co-Dx CEO Dwight Egan is expected to include a discussion about the upcoming Co-Dx PCR platform* and its pipeline of tests for COVID-19, tuberculosis, HPV, and an upper respiratory multiplex panel, as well as how Co-Diagnostics is positioned to address possible future health crises arising from infectious diseases such as human metapneumovirus (HMPV), H5N1, or avian flu, and mpox, formerly monkeypox.
The Company's existing Co-Dx™ Logix Smart® ABC (Influenza A/B & SARS-CoV-2) Test already detects all known circulating strains of H5N1 and is available for purchase by qualified centralized laboratories as a Research Use Only (RUO)** assay within the United States , and as an in vitro diagnostic (IVD) in regions that accept CE markings as valid regulatory clearance. Co-Diagnostics has also completed the principal design work and in silico analysis of an H5N1-specific target, which could be used as a standalone test or even added to the existing ABC test as needed.
Previously, the Company announced that the results of an analysis of the Co-Dx™ Logix Smart® Mpox (2-Gene) RUO test showed that the test should retain full reactivity against mpox strains circulating over the last year, including clade 1b , and Co-Diagnostics is prepared to launch an updated 3-gene version of this test, based on the needs of affected regions.
A post-holiday surge of COVID-19 has shown that the virus continues to be an unpredictable but persistent threat in the United States , as some experts warn that the pandemic is still ongoing and that COVID-19 remains dangerous.
Once available, the broadcast may be found on Nasdaq's Live from MarketSite webpage , as well as via the Company's social media platforms.
*The Co-Dx PCR platform (including the Co-Dx PCR Home™, Co-Dx PCR Pro™, mobile app, and all associated tests and software) is subject to review by the FDA and/or other regulatory bodies and is not available for sale. The Co-Dx PCR Pro instrument and Co-Dx COVID-19 Test are currently under review by the FDA.
**Co-Dx Logix Smart RUO tests are for research use only and not for use in diagnostic procedures.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform and to locate genetic markers for use in applications other than infectious disease.
Forward-Looking Statements:
This press release contains forward-looking statements. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Forward-looking statements include statements made with respect to our Co-Dx PCR platform and its pipeline of tests for COVID-19, tuberculosis, HPV, and an upper respiratory multiplex panel. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in our Risk Factors disclosure in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 14, 2024 , and in our other filings with the SEC. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
SOURCE Co-Diagnostics
FAQ**
What innovative advancements can we expect from Co-Diagnostics Inc. CODX in the development of the Co-Dx PCR platform, especially in the context of addressing future infectious disease threats?
How does Co-Diagnostics Inc. CODX plan to leverage its existing products like the Logix Smart ABC test to enhance its pipeline for emerging health crises such as H5N1 and mpox?
Can you discuss the regulatory process and anticipated timeline for the approval of the Co-Dx PCR Pro instrument and the associated COVID-19 Test currently under FDA review by Co-Diagnostics Inc. CODX?
With the ongoing challenges posed by COVID-19, what strategies is Co-Diagnostics Inc. CODX implementing to adapt its testing solutions in response to evolving variants and public health needs?
**MWN-AI FAQ is based on asking OpenAI questions about Co-Diagnostics Inc. (NASDAQ: CODX).
NASDAQ: CODX
CODX Trading
46.03% G/L:
$2.015 Last:
98,317,390 Volume:
$1.95 Open:
